IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: KE, Zhaoxi

Art Unit:

Serial No.: Not yet assigned

Examiner:

Filed: April 20, 2004

Atty. Docket: CL001313-DIV

For: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE

PROTEINS, AND USES THEREOF

Statement Regarding Duty to Disclose Information Material To Patentability Under 37 CFR 1.56 (a) and (b)

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

No fee is due for this submission. However, the Patent and Trademark Office is authorized to charge any necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

**CELERA GENOMICS** 

Date: April 20, 2004

Celera Genomics Corporation 45 West Gude Drive, C2-4#21

Rockville, MD 20850 Tel: 240-453-3812 Fax: 240-453-3084

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary).

Sheet: of

Complete if Known				
Application Number	Not yet assigned			
Filing Date	April 20, 2004			
First Named Inventor	Zhaoxi KE			
Art Unit				
Examiner Name				
Attorney Docket Number	CL001313-DIV			

	U.S. PATENT DOCUMENTS					
Examiner Initials		Document Number  Number-Kind Code <sup>2</sup> (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
gari, kanalang ja	ļ	US-	in lands managem (Manas Manas de Siriferista d'11), sum ga	فلادا المستهجين إدام المدافد الدارة الريادة والمسار الإدراء الم	specific a section is a consistent or common sold with the section of the section	
#1##### 141 #1##########################		US-	e twistingskippijgs ja storie is to i	go in the second of the control of t	and a second a second contraction of the second contraction is a second contraction of the second contraction of the second contraction is a second contraction of the second	
		US- "		en de (1700-1000) en derek en dels de la companya en de (1700-100) en de (1700-100) en de (1700-100) en de (17		
اند اطار الاستخداد الله الله الله الله الله الله الله ا	7	US-	atsmini, e.a. tra t	A 1 Matter a more games on memory or memory or many	and the second section of the second	
	No. 11.1	US	ا در شارو د دور ی تر پیستانید. در شارود دور ی تر پیستانید.	د برو بدر میخدد در در میکند به در در میکند به در	المنظمية المنظمة المنظ المنظمة المنظمة	
		US- US-	sandawaid Estifusiad dun fo a	der St. andere Cable et all designed designed as commenced assessment and cable and account about	س بن ميينين در در الله د کيمه بيشمين . در کين اگينيد در اين الله منظم اصف المتحد اساطه الله در هم الله اساله ا	
		US- US-	umatimizat etche sociale sesciale	e de la social de la section de la contraction d	e manus 2 haan si kikas ta makan sikan sikan sikan sikan sikikan sikikan sikikan sikan sikan sikan sikan si	
- 11 Hr =			ndarmaternak ing nyaka kenapadan ing	ى يەر ئەلىنىدىن دىدىنىگەدە ئىلىنىڭ ئېلىنىدىن بىلىنىڭ يېلىنىڭ دۇ.	g japa g V jahajajansa na manad ja siinnaga yynise si apa a fi int sassan. Ja ci anahaniin jahlija saannina a kanad ja kanad marangisjamsa, njiinnamangsa angisii (2 mg , ) an a sii (2 ma saanning njamananana a	
one a state.	4 i	US-	Lillian a stable a	, w	شاهر موسوم به نواز و در از در در این	
		.US-	Approximate to the second section of the se	and the state of t	allang og 1964 i stand symmetymen menmenskytterginen yn bygellynny yn meny amme yn menn yn menn yn bennedd Sallang og 1884 i 1885 og 1886 og 1886 og 1886 og 1886 og 1886	
majaja na panganan Salamah di 1844, 1844	g in the	US-	marman i z z steptaku i mieli iz i mi milie iz Cistatan intere i	ی در مرسیست مساست ساسه بیشد بیر ما در در باید و باشد بیر بر در در در بیرون بیش بیرون در در در در در در در در د کلاست در در در در مرسیست شمست کا در	era 1901 in er er er en hande en hereger de general de general en en er er er er en en en en en en en en en en 1901 in 1851 in 2005 in	
		US-	anderstands and the state of th	en ederscheit des eines des synthetische mit der	e sample agues de un gam paul — ma a entre s'eug, estador ha de féi an aguadadada da utilizada de utab agua mas -	

	FOREIGN PATENT DOCUMENTS						
Examiner		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages		
Initials	No.1	Country Code 3 -Number 4 - Kind Code 5 (I known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	<b>T6</b>	
		WO 98 11234 <sup>1</sup>	3/19/1998	Incyte Pharmaceuticals Inc.	whit carrenaids formure makenishes owns	. 3	
	1	EP 0 887 081 A2	12/30/1998	SmithKline Beecham Corp.			
to the terminal	:	EP 0 861 896 A2	09/02/1998	Dade Behring Marburg GmbH	يىلىمىيەر سىرىلىمىلىكىنىڭ ئاگىلىدىنىڭ دىك كەن ئىدىلىك ئالىلىنىڭ قالىدىدۇ. ئ	بيدعيد	
to see the second of	<del></del>	كالعدان الإنكام 1977 - 18 رائاتار بينه الانكاماني الدائم التيسامية واستواده الانتجاب الذياء والإنساول والموادم المدافعة	was rider trains become process.	and the Wild Man Color space where we have a set, who are not constant to the State of the State	de la matematica de dissembleme destrui de timo	general a	
ret in the silver		کیان جارج نے انہازی کا ایک کا انہاں کی سیادی افغیستا کا کامیا کیا، دینے عوامی کا انتظام انگاری کا انتظامی کا ک	ಚರ್ವಿ ಮುಗಳಪ್ರತಿ ಎಂದು ಪರೀಪಾಗಿಸುವ	and an artist of the second of	s valtudes a fiel er die der der de leiter bedeuten der de delet de		
ra maran	- ,	international of the department of the international of the state of t	करिलाहर सं १ १ व्या उत्तराहरू	and the state of t	ا براد الروم و در محمد الله الله الله الله الله الله الله الل		
e-Automor in il	***	ېرومدېمچې در ورمازېنهرومونونوه د و د د بوسونافلواهدوسسسه پسدسه کېدهوا مالله کمکاملوه پښاد و	der ver ferstomme e		وتمادك منطهر والمراجية والمراجية والمتكالين والمتاكات	-	
रकेल क्षेत्रकोड करण्य	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	way generalahan dalam da manan manan kembanan dan da ang ay	் இருள்ள இருந்து கொழிக்க நேர்	ا با دار در المیکند با میکند با است. در در داری پردید در بازی در این در این در این در این در این میکند در این میکند در این در در در در در در در در د	دري ټورکيون مختم مخصد د مصفحت پرېښترکيکې د د	h.tm/ini	
en in property	ألهما والفيتان	الل این پولود از اینها جادرونیا و اور اسپیشمیرسسسالساشنیدی مؤلفاتی پامیداشند	ಮೇವರ್ ಜಾರ್ಡ ನಡೆದಿನ ನಗರಗ ರ	مر پوسپسپدسیاسی سامی با بسامان و در ۱۰۰ بیده	-7.2-Wentin		
* # 100 januari 18 m		والأنافية أوالمراد الأسامة والموسيقة هيا الرسوم مشاو ميريين بين شيبيا المتفاسطة مناهد المستقل ما المعام المعام	and all specialists of the second of the second	e e e e e e e e e e e e e e e e e e e	ne neutral de la completa del la completa de la completa del la completa de la completa del la completa de la completa del la comple		

Francisco de la			_		
Examiner			Date		
Ciarrie III				į	
Signature	x = x = x = x = x = x = x = x = x = x =	** *** *** ***	Considered	1	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER:, Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as a total action to the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO Not yet assigned **Application Number** INFORMATION DISCLOSURE April 20, 2004 Filing Date Zhaoxi KE STATEMENT BY APPLICANT **First Named Inventor Group Art Unit Examiner Name** (use as many sheets as necessary) Attorney Docket Number Sheet 2 of 2 CL001313-DIV

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner ; Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
معدود سامو		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAW90139, KUMAN JM, March 1999.	
د ایس، المس		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAW77217, LANG et al., November 1998.	
ಕರ್ಮಾಕರ ಬಿಜ		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAB2115, YU et al., January 2001.	
	e attaclar c	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAB65613, PLOWMAN et al., March 2001.	
i o servi sensi ilmin u	e second as a	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAW52025, AU-YOUNG et al., March 2001.	2-1-
. E niv siran		EP 0 887081 A2 (SMITHKLINE BEECHAM CORP) 30 December 1998 (30.12.1998) see entire document.	
Province of the second states of the	SHI, YE	EP 0 861896-A2 (DADE BEHRING MARBUG GMBH) 02 September 1998 (02.09.1998) see entire document.	
2 only majoring		WO 98/11234-A2 (INCYTE PHARM INC.) 19 March 1998 (19.03.1998) see entire document.	
,		International Search Report dated January 15, 2004.	
or Tayle (AT and a		سان و المارة الإيلى المراوعة المستواد المستود المستواد المستواد المستود الم	) and 19 Mary
		_	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.